Navigation Links
Regeneron Pharmaceuticals Announces Proposed Offering of Convertible Senior Notes due 2016
Date:10/17/2011

TARRYTOWN, N.Y., Oct. 17, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) (the "Company") announced that it intends to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior notes due 2016 in a private placement.  The notes will be offered by the initial purchaser only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.  The Company also intends to grant to the initial purchaser a 13-day option to purchase up to an additional $60 million aggregate principal amount of notes on the same terms and conditions.

The Company intends to use a portion of the proceeds of the offering, together with the proceeds from the warrant transactions, to fund the cost of the convertible note hedge transactions in connection with the offering, each as described below.  The Company intends to use the remaining net proceeds for general corporate purposes.

The notes will be general senior unsecured obligations of the Company.  The notes will be convertible, subject to certain conditions, into cash, shares of common stock of the Company, or a combination of cash and stock, at the Company's option.  The notes will mature on October 1, 2016 unless previously repurchased or converted in accordance with their terms prior to such date.  The interest rate, conversion rate, conversion price and other terms of the notes will be determined at the time of the pricing of the offering.

In connection with the offering of the notes, the Company plans to enter into privately negotiated convertible note hedge and warrant transactions with counterparties that may include the initial purchaser and/or its affiliates.  The convertible note hedge transactions will cover, subject to customary anti-dilution adjustments, the number of shares of the Compa
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Regeneron Announces Appointment of Joseph J. LaRosa as Senior Vice President, General Counsel and Secretary
2. Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
3. Regeneron Announces Presentation at the 29th Annual J.P. Morgan Healthcare Conference
4. Regeneron Announces Presentation at the 2010 Deutsche Bank BioFest
5. Regenerons Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
6. Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview
7. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
8. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings
9. Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B
10. Elevation Pharmaceuticals Presents Positive Phase 2a Results in COPD Patients at the European Respiratory Society Annual Congress
11. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Atlanta, GA (PRWEB) May 06, 2015 ... solutions based on the products of cells grown ... on its 105F immunomodulatory treatment candidate for melanoma ... Annual Meeting, taking place May 6-9, 2015 in ... hypoxia-induced multipotent cells produce a soluble material with ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 The ... and growth strategy for the specialty pharmacy industry, will ... the 2015 Armada Specialty Pharmacy Summit. The Summit will ... in Las Vegas and is the largest annual gathering ... be in attendance, from pharmacy providers, pharma/biotech manufacturers, and ...
(Date:5/5/2015)... , May 5, 2015  Blueprint Medicines ... of its initial public offering of 9,367,708 shares ... of $18.00 per share, including shares of common ... underwriters of their option to purchase additional shares. ... to Blueprint Medicines were approximately $168.6 million, before underwriting ...
(Date:5/5/2015)... May 5, 2015 Roka Bioscience, Inc. (NASDAQ: ... testing solutions for the detection of foodborne pathogens,  today announced ... Bank of America Merrill Lynch 2015 Health Care Conference on ... at Encore at the Wynn, Las Vegas NV. ... presentation will be available through the investor relations section of ...
Breaking Biology Technology:Novel Immunomodulatory Treatment Induces Apoptosis in Melanoma 2The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 2Blueprint Medicines Announces Closing of Initial Public Offering 2
... passed a bill that will make it easier for ... two other bills endorsed by the technology community are ... legislative session. , ,On separate voice votes, the State ... of Senate Bill 338, which would streamline the process ...
... about cutting government spending and holding the line on taxes ... really want to bite the bullet? , ,Based on what ... likely to happen this week in the state Senate, the ... Capitol accurately reflects the mood of most voters, who are ...
... - With the goal of improving patient safety, ... five years, the Wheaton Franciscan Healthcare system ... , ,Wheaton, a Catholic, not-for-profit healthcare ministry, will use ... McKesson Corp ., a Fortune 500 company that ...
Cached Biology Technology:Legislature adopts one tech bill, leaves two others twisting 2Legislature adopts one tech bill, leaves two others twisting 3Legislature adopts one tech bill, leaves two others twisting 4In public attitudes about taxes and spending, Wisconsin is Jekyll and Hyde 2In public attitudes about taxes and spending, Wisconsin is Jekyll and Hyde 3
(Date:4/8/2015)...  Infinisource, a leading provider of SaaS-based Human Capital ... leading supplier of biometric identification and security solutions, ... advanced biometrically-enabled time clock, the companies announced today. ... setting a bold, new standard for the collection ... and mid-size employer. When connected to the iSolved ...
(Date:4/2/2015)... April 2, 2015 According to ... attributed to somewhat higher than 125 MSEK. This exceeds ... report 2014 that revenues for Q1 2015 would be ... reported for Q4 2014. The operating result for the ... The complete interim report will as previously communicated be ...
(Date:3/31/2015)... 2015  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ... Software Defined Network Architecture (ET Software DNA® 2.0) platforms ... approximately $20.4 million for the year ended December 31, ... the year ended December 31, 2013. ... completed its multi-year transition away from its legacy landline ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... could see humble cotton thread emerge as a core ... such as kidney failure and diabetes. In a ... and sewing needles to literally stitch,together the uniquely low-cost ... postage stamp. Microfluidic analytical devices, which have been ...
... University of Wisconsin-Madison engineers has developed a highly ... a biomass derivative, into the chemical equivalent of ... 95 percent of the energy from the original ... dioxide under high pressure for future beneficial use. ...
... new University of Colorado at Boulder study shows mice ... with a deadly and poorly understood human inflammatory disease, ... The human disease, known as Hemophagocytic Lymphohistiocytosis, or HLH, ... percent and 90 percent of its victims, said Diane ...
Cached Biology News:How long is a piece of thread? Long enough to save a life 2New process yields high-energy-density, plant-based transportation fuel 2New University of Colorado paper shows novel way to study human inflammatory disease 2
... Cultures (ECACC) in conjunction with the Univeristy ... England, Bristol, UK, have produced standardised cell ... oestrogen and progresterone receptor assays. The slides ... fixed, breast cancer cell lines; MDA-MD-361, T47D, ...
kismet (dK-20)...
... potent TURBO DNase (patent pending) in the TURBO ... DNA removal capabilities. TURBO DNase is a recombinant, ... more efficient than wild type DNase I in ... DNase binds DNA substrates 6-fold more tightly than ...
...
Biology Products: